Abstract
Introduction
Secondary prophylaxis to prevent rheumatic heart disease (RHD) progression, in the form of four-weekly intramuscular benzathine benzylpenicillin G (BPG) injections, has remained unchanged since 1955. Qualitative investigations into patient preference have highlighted the need for long-acting penicillins to be delivered less frequently, ideally with reduced pain. We describe the experience of healthy volunteers participating in a phase-I safety, tolerability and pharmacokinetic trial of subcutaneous infusions of high-dose benzathine penicillin G (BPG)–the SCIP study (Australian New Zealand Clinical Trials Registry ACTRN12622000916741).
Methods
Participants (n = 24) received between 6.9 mL to 20.7 mL (3–9 times the standard dose) of BPG as a single infusion into the abdominal subcutaneous tissues via a spring-driven syringe pump over approximately 20 minutes. Semi-structured interviews at four time points were recorded, transcribed verbatim and thematically analysed. Tolerability and specific descriptors of the experience were explored, alongside thoughts on how the intervention could be improved for future trials in children and young adults receiving monthly BPG intramuscular injections for RHD.
Results
Participants tolerated the infusion well and were able describe their experiences throughout. Most reported minimal pain, substantiated via quantitative pain scores. Abdominal bruising at the infusion site did not concern participants nor impair normal activities. Insight into how SCIP could be improved for children included the use of topical analgesia, distractions via television or personal devices, a drawn-out infusion time with reduced delivery speed, and alternative infusion sites. Trust in the trial team was high.
Conclusion
Qualitative research is an important adjunct for early-phase clinical trials, particularly when adherence to the planned intervention is a key driver of success. These results will inform later-phase SCIP trials in people living with RHD and other indications.
Funder
Cure Kids
Strep A PhD Scholarship and a Scholarship for International Research Fees
Post Graduate Research Scholarship & Althestan Saw Bequest Fund
National Health and Medical Research Council
Research Training Program
Wesfarmers Centre of Vaccines and Infectious Diseases Top Up scholarship
Publisher
Public Library of Science (PLoS)
Reference35 articles.
1. Jones Criteria (Modified) for Guidance in the Diagnosis of Rheumatic Fever: Report of the Committee on Standards and Criteria for Programs of Care;DD Rutstein;Circulation,1956
2. Pfizer Australia Pty Ltd. Australian product information–Bicillin L-A (Benzathine benzylpenicillin tetrahydrate) suspension for injection. 2022. http://secure.healthlinks.net.au/content/pf/retriever.cfm?product=pfpbacii10912 (accessed 3 March 2022).
3. RHDAustralia (ARF/RHD writing group). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (3rd edition). Darwin: Menzies School of Health Research, 2020.
4. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study;GA Roth;J Am Coll Cardiol,2020
5. The global burden of group A streptococcal diseases;JR Carapetis;Lancet Infect Dis,2005
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献